Gain-of-function mutations in SHP-2͞PTPN11 cause Noonan syndrome, a human developmental disorder. Noonan syndrome is characterized by proportionate short stature, facial dysmorphia, increased risk of leukemia, and congenital heart defects in Ϸ50% of cases. Congenital heart abnormalities are common in Noonan syndrome, but the signaling pathway(s) linking gain-of-function SHP-2 mutants to heart disease is unclear. Diverse cell types coordinate cardiac morphogenesis, which is regulated by calcium (Ca 2؉ ) and the nuclear factor of activated T-cells (NFAT). It has been shown that the frequency of Ca 2؉ oscillations regulates NFAT activity. Here, we show that in fibroblasts, Ca 2؉ oscillations in response to FGF-2 require the phosphatase activity of SHP-2. Conversely, gain-of-function mutants of SHP-2 enhanced FGF-2-mediated Ca 2؉ oscillations in fibroblasts and spontaneous Ca 2؉ oscillations in cardiomyocytes. The enhanced frequency of cardiomyocyte Ca 2؉ oscillations induced by a gain-of-function SHP-2 mutant correlated with reduced nuclear translocation and transcriptional activity of NFAT. These data imply that gain-of-function SHP-2 mutants disrupt the Ca 2؉ oscillatory control of NFAT, suggesting a potential mechanism for congenital heart defects in Noonan syndrome.
T
he ubiquitously expressed src homology 2 (SH2)-containing protein tyrosine phosphatase (PTP), SHP-2 (PTPN11), regulates numerous intracellular signaling cascades that control cell proliferation, differentiation, cell survival, migration, adhesion, and apoptosis (1) . SHP-2 contains two NH 2 terminus SH2 domains, a PTP domain, and a COOH terminus containing two tyrosyl phosphorylation sites (1) . It is now well established that SHP-2 is required for activation of the extracellular-regulated kinases (ERKs) 1 and 2 in response to the activation of receptor tyrosine kinase (RTK) and cytokine receptors (1) . The SH2 domains of SHP-2 mediate not only binding to RTKs but also scaffold proteins such as Gab-1, IRS-1, and FRS-2 (1) . In virtually all cases, stimulation of SHP-2 catalysis is required for downstream signaling. The SH2 domains of SHP-2 also regulate its activation. Engagement of the NH 2 SH2 domain of SHP-2 with its cognate phosphotyrosyl protein results in its activation. The mechanism of this activation involves displacement of the NH 2 SH2 domain from the PTP domain which in the basal (unbound SH2 domain) state occludes the PTP active site. Upon NH 2 SH2 domain binding, a conformational relief of this inhibitory state is achieved and the phosphatase becomes active. Insights from the crystallographic structure of SHP-2 (2) resulted in the generation of engineered mutations at residues critical for the maintenance of the basal inactivated state of SHP-2. These mutations, within the NH 2 SH2 domain of SHP-2 (e.g., E76A), generated a constitutively active (gain-of-function) form of SHP-2 that is still capable of interacting appropriately with its upstream phosphotyrosyl target (3) .
Genetic disruption of SHP-2 expression in mice results in early embryonic lethality (4) . During embryogenesis, SHP-2 has been implicated in the formation of cardiac semilunar valvulogenesis and limb development (5, 6) . Germ-line missense mutations of human PTPN11, which encodes SHP-2, cause Noonan syndrome, a human autosomal dominant disorder that occurs with an incidence between 1 in 1,000 and 1 in 2,500 live births (7) (8) (9) (10) . Mutations in SHP-2 that are associated with Noonan syndrome result in its constitutive activation (11) . Noonan syndrome is a clinically heterogenous disorder defined by facial dysmorphia and proportionate short stature (7, 8) . Congenital heart disease is present in up to 85% of Noonan syndrome patients, constituting the most common nonchromosomal cause of congenital heart disease (7). Pulmonic stenosis is a common form of cardiac disease in Noonan syndrome with a lesser frequency of occurrence of atrioventricular, ventricular septal, and hypertrophic cardiomyopathy. A knock-in mouse model of the Noonan syndrome mutant, D61G, exhibits similar cardiac defects in the atrioventricular and outflow-tract valves (12) . These observations support a causal role for SHP-2 gain-of-function mutants in cardiac pathogenesis. Cardiac morphogenesis depends on intracellular calcium (Ca 2ϩ ), which activates the calcineurin͞ nuclear factor of activated T-cells (NFAT) pathway (13) (14) (15) (16) . The regulation of calcineurin by Ca 2ϩ is complex because calcineurin͞ NFAT activity is stimulated not merely by an influx of intracellular Ca 2ϩ , but also by the oscillatory frequency of intracellular Ca 2ϩ transients (17) (18) (19) . Given the fundamental role of Ca 2ϩ in the regulation of gene expression and activity, we tested whether SHP-2 regulates Ca 2ϩ signaling, and if so, whether Ca 2ϩ is a target of the effects of gain-of-function SHP-2 mutants that are associated with Noonan syndrome.
Results

SHP-2 Is
Required for RTK-Induced Ca 2؉ Signaling. We first examined Ca 2ϩ signaling in fibroblasts derived from mice containing a deletion within exon 3 of SHP-2 (SHP-2 Ex3Ϫ/Ϫ ) that results in the truncation of its NH 2 terminus SH2 domain (4) . SHP-2 Ex3Ϫ/Ϫ fibroblasts exhibit properties consistent with a loss of SHP-2 function. Both wild-type (WT) (SHP-2 ϩ/ϩ ) and SHP-2 Ex3Ϫ/Ϫ fibroblasts loaded with Fluo-4͞AM responded to ATP, a G protein coupled receptor agonist, by increasing their levels of intracellular Ca 2ϩ ( Fig. 1 a and b and Table 1 ). Similar results were obtained when fibroblasts were exposed to another G protein coupled receptor agonist, bradykinin (data not shown). When fibroblasts were stimulated with platelet-derived growth factor (PDGF), a transient increase in Ca 2ϩ was observed in SHP-2 ϩ/ϩ , but not in SHP-2 Ex3Ϫ/Ϫ , fibroblasts ( Fig. 1 c and d and Table 1 ). Exposing SHP-2 Ex3Ϫ/Ϫ fibroblasts to ATP after stimulation with PDGF, however, resulted in a Ca 2ϩ transient (Fig. 1d ). (Fig. 1g) , indicating that internal endoplasmic reticulum Ca 2ϩ stores were equally intact. Thapsigargin, also a SERCA inhibitor, gave comparable responses (see Fig. 5 a and b, which is published as supporting information on the PNAS web site). Neither FGF-2 nor PDGF evoked Ca 2ϩ responses in SHP-2 ϩ/ϩ fibroblasts after internal Ca 2ϩ stores were depleted after CPA stimulation (Fig. 5c) . Mobilization of intracellular Ca 2ϩ is mediated by the inositol 1,4,5-trisphosphate receptor (InsP 3 R) (20) . Preincubation of fibroblasts with the InsP 3 R inhibitor, 2-aminoethoxydiphenyl borate (2-APB) blocked FGF-2-and PDGF-induced Ca 2ϩ responses (Fig. 5d) . Thus, PDGF and FGF-2 regulate InsP 3 R- (Fig. 1h) ; the type 2 InsP 3 R, however, was undetectable. Similar subcellular distribution in SHP-2 ϩ/ϩ and SHP-2 Ex3Ϫ/Ϫ fibroblasts were observed for both type 1 and 3 InsP 3 Rs (Fig. 1i) . To determine whether SHP-2 Ex3Ϫ/Ϫ fibroblasts express the FGF receptor to levels equivalent to that of SHP-2 ϩ/ϩ fibroblasts, we used purified GFP-tagged FGF protein (FGF-GFP) to label these cells. When FGF-GFP was exposed to these fibroblasts, similar levels of plasma membrane FGF-GFP fluorescence was observed in SHP-2 ϩ/ϩ and SHP-2 Ex3Ϫ/Ϫ fibroblasts (see Fig. 6 a and b, which is published as supporting information on the PNAS web site). Together, these results support the interpretation that the impaired Ca 2ϩ signaling in SHP-2 Ex3Ϫ/Ϫ fibroblasts is due to a loss of SHP-2 function rather than defects in the Ca 2ϩ -generating machinery.
To definitively establish that SHP-2 is responsible for FGF- Fig. 1k ). These results demonstrate that loss of SHP-2 is causally related to the attenuated Ca 2ϩ response and that the catalytic activity of SHP-2 is required to generate FGF-2-induced Ca 2ϩ oscillations.
SHP-2 Gain-of-Function and Noonan Syndrome Mutations Enhance
Ca 2؉ Oscillatory Frequency. Because the catalytic activity of SHP-2 is required to mediate Ca 2ϩ signaling in response to FGF-2 ( Fig.  1k) , we tested the effects of a constitutively active mutant of SHP-2 (Table 2) on FGF-2-induced Ca 2ϩ oscillations. A mutation within the NH 2 terminus SH2 domain of SHP-2 at Glu-76 to Ala-76 (SHP-2 E76A ) has been shown to result in constitutive SHP-2 catalysis (3). As compared with vector and SHP-2 WT expressing fibroblasts, SHP-2 E76A expressing fibroblasts exhibited an enhanced oscillatory frequency in response to FGF-2 ( Fig. 2 a-c ; see also Movie 1, which is published as supporting information on the PNAS web site). To quantitate the oscillatory behavior of this response, we performed a spectral analysis (21) oscillations with a frequency of 9.6 Ϯ 1.4 mHz (n ϭ 25) and 12.6 Ϯ 1.0 mHz (n ϭ 25), respectively ( (9, 22) ; therefore, we tested whether a gain-of-function mutant of SHP-2 found in Noonan syndrome (Table 2) enhances FGF-2-induced Ca 2ϩ oscillatory frequency. Fibroblasts were transfected with a SHP-2 Noonan syndrome mutant in which Asp-61 is mutated to Gly-61 (SHP-2 D61G ) (10, 11). We found that when expressed in fibroblasts, SHP-2 D61G also enhanced the oscillatory response evoked by FGF-2 by Ϸ2-fold to 21.7 Ϯ 1.8 mHz (n ϭ 19) (Figs. 2 d and e and 7d) cytosol, resulting in its translocation to the nucleus (16) . Cardiac morphogenesis relies on Ca 2ϩ and subsequently the precise regulation of the calcineurin͞NFAT pathway (14) (15) (16) . NFAT functions in numerous cellular processes, one of which involves the activation of transcription factors that regulate cardiac development (23, 24) . We hypothesized that gain-of-function SHP-2 mutants would enhance Ca 2ϩ oscillations in cardiomyocytes similar to those observed in fibroblasts (Fig. 2 e and f ) . Moreover, we speculated that altered Ca 2ϩ oscillations in cardiomyocytes could interfere with calcineurin-dependent regulation of NFAT. To test this hypothesis, primary rat cardiomyocytes were first transfected with vector alone. We found that cardiomyocytes exhibited spontaneous Ca 2ϩ oscillations with a frequency of 28.6 Ϯ 5.2 mHz and FDHM of 8.3 Ϯ 0.5 s (Figs 3 a, e, and f and 7e) . Significantly, cardiomyocytes expressing SHP-2 WT exhibited spontaneous Ca 2ϩ oscillations with a frequency of 131.2 Ϯ 17.5 mHz and FDHM of 4.5 Ϯ 0.3 s (Figs. 3 b, e , and f and 7f ), whereas SHP-2 E76A cardiomyocytes responded with a spontaneous Ca 2ϩ oscillation frequency of 190.5 Ϯ 15.1 mHz and FDHM of 4.3 Ϯ 0.5 s (Figs. 3 c, e, and f and 7g) . Importantly, expression of the catalytically inactive mutant of SHP-2, SHP-2 R465M , was without effect as compared with vector control transfected cardiomyocytes (31.3 Ϯ 6.4 mHz and 9.0 Ϯ 1.3 s) (Figs. 3 d , e, and f and 7h). These data imply that constitutive SHP-2 activity gives rise to an increase in cardiomyocyte Ca 2ϩ oscillatory frequency.
Suppression of NFAT Activation in Cardiomyocytes by Gain-of-Function SHP-2 Mutants.
The oscillatory frequency of Ca 2ϩ has been reported to be a mechanism in which calcineurin͞NFAT activation can be ''fine-tuned'' (17-19). Moreover, NFATc1-deficient mice have defects in the formation of heart valves and the interventricular septum that resemble congenital heart defects seen in humans (23, 24) . Therefore, we investigated whether enhanced SHP-2 activity affected NFAT function in cardiomyocytes. When immunostaining for NFATc1 was performed in cardiomyocytes infected with an adenovirus expressing GFP alone, an equal distribution of endogenous NFATc1 expression was observed between the nucleus and cytoplasm (Fig. 4 a and b) . In contrast, cardiomyocytes infected with an adenovirus expressing SHP-2 E76A showed decreased nuclear expression of NFATc1 (Fig. 4 c and d) . Nuclear to cytosolic expression of NFATc1 in cardiomyocytes was quantitated for vector, SHP-2 WT , SHP-2 E76A and SHP-2 R465M (Fig. 4e) . This analysis showed that SHP-2 E76A -expressing cardiomyocytes contained Ϸ40% less nuclear localized NFATc1 as compared with SHP-2 WTexpressing cardiomyocytes (Fig. 4e) . Moreover, the catalytically inactive mutant of SHP-2, SHP-2 R465M , displayed levels of nuclear NFATc1 accumulation similar to that of cardiomyocytes infected with vector and SHP-2 WT . These results suggest that a gain-offunction mutant of SHP-2 impairs NFATc1 nuclear localization and by inference NFAT transcriptional activity in cardiomyocytes. To confirm that NFAT transcriptional activity is functionally impaired by SHP-2 E76A , cardiomyocytes were coinfected with an adenoviral luciferase reporter gene driven by a NFAT minimal DNA-binding element, along with adenoviruses encoding either vector, SHP-2 WT , SHP-2 E76A , or SHP-2 R465M . This experiment demonstrated that SHP-2 E76A significantly inhibited NFAT activity by Ϸ30% as compared with SHP-2 WT -infected cardiomyocytes (Fig. 4f ) . Expression of SHP-2 WT was found to inhibit NFAT activity in cardiomyocytes. This result could be due to the observation that overexpressed SHP-2 WT also increased Ca 2ϩ oscillatory frequency relative to vector control transfectants. However, the enhanced Ca 2ϩ oscilla- tory frequency seen in SHP-2 WT as compared with SHP-2 E76A was not due to differences in the expression of SHP-2 because immunoblotting of the same lysates used for the NFAT reporter gene experiments showed comparable levels of SHP-2 in SHP-2 WT -and SHP-2 E76A -expressing cardiomyocytes (Fig. 4g) . Significantly, NFAT activity in SHP-2 R465M -expressing cardiomyocytes was not inhibited, although SHP-2 R465M was overexpressed relative to vector control-infected cardiomyocytes (Fig. 4 f and g ). These results support the interpretation that enhanced SHP-2 activity suppresses NFAT activation. Finally, we performed a two-way analysis, correlating NFAT activity in response to the expression of SHP-2 WT , SHP-2 E76A , and SHP-2 R465M with their respective Ca 2ϩ oscillatory frequencies generated in cardiomyocytes. This analysis revealed a correlation coefficient of r 2 ϭ 0.96 for vector, SHP-2 WT , SHP-2 E76A , and SHP-2 R465M vs. their respective cardiomyocyte Ca 2ϩ oscillatory frequencies (Fig. 4h) . Thus, SHP-2 catalysis correlates with an increase in Ca 2ϩ oscillatory frequency and suppression of NFAT activation in cardiomyocytes.
Discussion
Our data show that SHP-2 is responsible for evoking distinct Ca 2ϩ responses after stimulation of fibroblasts with either PDGF or FGF-2. We found that PDGF produced a Ca 2ϩ transient whereas FGF-2 generated Ca 2ϩ oscillations, and in both of these cases Ca 2ϩ responses were abrogated in fibroblasts lacking functional SHP-2. Importantly, SHP-2 does not participate in all receptor-mediated Ca 2ϩ signaling pathways because loss of functional SHP-2 in fibroblasts still resulted in Ca 2ϩ mobilization upon activation of the G protein-coupled P2Y receptor. These data demonstrate that SHP-2 is responsible for generating Ca 2ϩ responses downstream of RTKs but not G-protein-coupled receptors. Furthermore, SHP-2 appears to mediate distinct Ca 2ϩ responses among different RTKs. How SHP-2 regulates Ca 2ϩ transients and oscillations, however, remains to be established. The Src-family kinases can activate phospholipase C␥1, which mediates the release of InsP 3 and subsequently Ca 2ϩ mobilization. The catalytic activity of SHP-2 has been shown to be responsible for the activation of the Src-family kinases (25) . Thus, Src-family kinase phosphorylation of phospholipase C␥1 mediated by SHP-2 in response to RTK activation is one candidate pathway through which SHP-2 may mediate Ca 2ϩ release. Indeed, it was shown recently that SHP-2 is required for the mobilization of Ca 2ϩ in response to interleukin-1 by a mechanism involving phospholipase C␥1 tyrosine phosphorylation (26) . Our data support this idea because we show specifically that the catalytic activity of SHP-2 is required for FGF-2-induced Ca 2ϩ mobilization.
One of the key findings of this work is that enhanced catalytic activity of SHP-2 rendered by a gain-of-function mutation resulted in a significant increase in the Ca 2ϩ oscillatory frequency and a significant FDHM decrease in response to FGF-2 in fibroblasts and primary cardiomyocytes. Gain-of-function SHP-2 mutants have been shown to cause hyperactivation of the extracellular-regulated kinases (ERKs) and to increase cell proliferation (11) . Our results now show that the Ca 2ϩ signaling pathway is also a target for aberrant regulation by gain-of-function SHP-2 mutants. Many mutations in SHP-2 that are associated with Noonan syndrome occur at the interface between the PTP domain and NH 2 -terminal SH2 domain resulting in its constitutive activation (9) . We show that in addition to the gain-of-function SHP-2 E76A mutant, SHP-2 D61G mutation, which is found in Noonan syndrome patients, also resulted in enhanced Ca 2ϩ oscillatory frequency and decreased FDHM in response to FGF-2. Therefore, our results suggest that altered Ca 2ϩ signaling, conferred by SHP-2 gain-of-function mutants found in Noonan syndrome, may be a related molecular mechanism associated with the pathogenesis of this disease. Interestingly, patients with Leopard syndrome, a closely related developmental disorder to that of Noonan syndrome in which SHP-2 mutations have been identified, suffer from electrocardiographic conduction abnormalities (10) . Our observation that gain-offunction SHP-2 mutants disrupt the ''pacemaker'' feature of cardiomyocytes provides insight into potential mechanisms for why Leopard syndrome patients manifest with electrocardiographic conduction defects.
Noonan syndrome patients often present with cardiovascular abnormalities, primarily congenital heart diseases in up to 85% of affected individuals. The most prevalent form of congenital heart disease in Noonan syndrome is pulmonic stenosis, in addition to other lesions such as atrioventricular septal defects, mitral valve abnormalities, and hypertrophic cardiomyopathy (7, 8) . A number of signaling pathways have been implicated in cardiac morphogenesis. Notably, the NFAT signaling pathway has been shown to be critical for cardiac development and is regulated by Ca 2ϩ through the actions of calcineurin (13) (14) (15) (16) . We tested the hypothesis that altered Ca 2ϩ signaling evoked by SHP-2 gain-of-function mutations might disrupt NFAT function. Our data demonstrate that enhanced Ca 2ϩ oscillatory frequency induced by SHP-2 gain-of-function mutants in cardiomyocytes correlates with the inhibition of NFAT translocation to the nucleus and subsequently suppression of NFAT transcriptional activity. These data implicate NFAT as a target of SHP-2 gain-of-function͞Noonan syndrome mutants. Provocatively, altered NFAT function in mice through genetic ablation gives rise to valvulogenesis defects (23, 24) that bear some similarity to the congenital heart defects observed in a mouse model of Noonan syndrome (12) . There is good evidence that calcineurin which activates NFAT by dephosphorylation is regulated not just by increases in intracellular Ca 2ϩ but also by the oscillatory frequency of Ca 2ϩ (27) . After NFAT translocation to the nucleus, it also has been shown that NFAT transcriptional activity is modulated by the frequency of intracellular Ca 2ϩ oscillations (17, 18) . The fact that SHP-2 gain-of-function mutations decreased the FDHM also might contribute to the NFAT transcriptional activity. Thus, it is conceivable that altered Ca 2ϩ signaling and͞or disruption of the NFAT function by Noonan syndrome mutants may contribute to the development of congenital heart abnormalities.
In summary, we show that the catalytic activity of SHP-2 is required for FGF-2-induced Ca 2ϩ oscillations in fibroblasts. Moreover, constitutive SHP-2 catalysis, as exhibited in gain-of-function͞ Noonan syndrome SHP-2 mutations, resulted in enhanced Ca 2ϩ oscillatory frequency in response to FGF-2 in fibroblasts and spontaneous Ca 2ϩ oscillations in cardiomyocytes. Both the FGF and the Ca 2ϩ ͞calcineurin͞NFAT pathways are critical for cardiac morphogenesis (14, 28) . SHP-2 gain-of-function mutants perturb the Ca 2ϩ oscillatory frequency downstream of the FGF receptor, which could contribute to abnormal cardiac morphogenesis. Perturbations in NFAT function through dysregulation of the Ca 2ϩ ͞ calcineurin͞NFAT axis in cardiomyocytes also appears to be a pathway through which gain-of-function͞Noonan syndrome mutants of SHP-2 may disrupt cardiac valvulogenesis (14) . Collectively, these results provide a potential mechanistic link between SHP-2 gain-of-function mutants and the development of congenital heart disease seen in Noonan syndrome.
Materials and Methods
Cell Cultures. Fibroblasts derived from mice containing either a deletion within exon 3 of SHP-2 that removes amino acids 46-110 of the NH 2 terminus SH2 domain (SHP-2 Ex3Ϫ/Ϫ ) or from WT (SHP-2 ϩ/ϩ ) littermate controls are described in refs. 4 and 29. Briefly, cells were cultured at 37°C and 5% CO 2 in DMEM (Invitrogen) containing 10% FBS (Sigma), 1 mM sodium pyruvate (Invitrogen), 5 units͞ml penicillin, and 50 g͞ml streptomycin (Sigma). Cardiac myocytes were prepared as described in ref. 30 . Primary cultures of cardiomyocytes were cultured from hearts of 1-to 3-day-old Sprague-Dawley rats seeded on gelatin-coated coverslips and starved in serum-free medium 24 h prior to the experiment. The protocol produces cultures of cardiac myocytes that are at least 95% pure (30) .
